Background {#Sec1}
==========

Vanishing bile duct syndrome (VBDS) is defined as an intrahepatic cholestasis with paucity of interlobular bile ducts \[[@CR1]\]. The cause is unknown and it has been associated with different pathologic conditions: adverse drug reactions, autoimmune diseases, graft versus host disease, and cancer. These associations make the immune-mediated pathogenesis the most likely one. Histology is characterized by marked cholestasis without evidences of an accompanying hepatitis, but with a characteristic loss of bile ducts in the portal tracts. Clinical outcome is hepatic failure unless the underlying disease can be appropriately cured. We present a case of a VBDS that heralded the successive diagnosis of Hodgkin's lymphoma (HL).

Case presentation {#Sec2}
=================

A 42-year-old Caucasian woman was admitted to an infectious disease unit because of jaundice and fever. Her medical past history was unremarkable except for a mild allergy to cat hair. On admission her abnormal chemical tests were: total and direct bilirubin of 18.3 milligrams/deciliter (mg/dL) and 15.3 mg/dL, respectively (normal value up to 1.3 and 0.4 mg/dL, respectively); aspartate (AST) and alanine aminotransferase (ALT), 151 and 322, respectively (normal value up to 35 units/liter (U/L) and 40 U/L, respectively); alkaline phosphatase (ALP) 322 U/L (normal value up to 240 U/L); gamma-glutamyl transpeptidase (GGT) 482 U/L (normal value up to 35 U/L). Blood counts were normal except for leukocytosis (15170/μL). The patient was not taking any drug, and an extensive infectious disease work-up was negative. Particularly, hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) were excluded as well as Epstein-Barr virus (EBV) and cytomegalovirus (CMV). A computed tomography (CT) scan showed enlarged mediastinal lymph nodes without any abdominal pathological feature, and no sign of biliary tract dilatation. At that time, the patient was referred to our center, and a mediastinal biopsy was performed showing a picture of classic HL of nodular sclerosis histotype. Furthermore, the most common antibodies responsible for autoimmune hepatitis (ANA - antinuclear antibodies, ASMA -- anti-smooth-muscle antibodies, anti-LKM1 -- anti-liver-kidney microsomal type 1, anti-SLA - antibodies against soluble liver antigen, AMA - antimitochondrial antibody, antiphospholipid antibodies) were evaluated without any pathological findings. Since biochemical cholestasis had worsened (total bilirubin 33.8 mg/dL), a hepatic biopsy was performed showing marked cellular and canalicular perivenous cholestasis. Remarkably, bile ducts were absent (Figure [1](#Fig1){ref-type="fig"}) in all seven portal tracts examined and no sign of HL could be detected in a picture consistent with a VBDS \[[@CR1]\]. Bone marrow trephine was negative. We also carried out a positron emission tomography (PET) scan that showed increased 18 F-fluoro-deoxy-glucose (18 F-FDG) uptake in multiple mediastinal lymph nodes defining a stage IIB HL. She was started on ursodeoxycholic acid (UDCA) (1350 mg daily) and prednisone (50 mg daily). A dramatic improvement of her clinical and biochemical conditions occurred with a decreased total bilirubin to 10 mg/dL. At this point, doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy was delivered and, after 4 cycles, we performed interim restaging with the PET scan showing a complete response. Therefore, she subsequently received two additional cycles of ABVD with a complete response confirmed after six cycles. Despite the fact that total bilirubin was increased at the time of the first cycle, we delivered a full dose of doxorubicin and vinblastine. At completion, prednisone was tapered and UDCA interrupted. The patient declined to receive a hepatic biopsy at the end of chemotherapy. Six years later, she is still in complete remission with a thoroughly normal hepatic function.Figure 1**Paraffin embedded section of the liver biopsy stained in hematoxylin-eosin showing fibrotic portal spaces without evidence of biliary interlobular ducts.** (Panel **A** 5x magnification, Panel **B** 20x magnification, Panel **C** 40x magnification).

Conclusion {#Sec3}
==========

Several conditions may cause jaundice in HL. Biliary obstruction secondary to lymph nodes enlargement, hemolysis, hepatotropic and other viruses (e.g. CMV) are among the most common causes. Hepatic direct involvement by HL is a relatively rare, but well known complication \[[@CR2]\]. The association of cholestatic jaundice and hepatic bile duct loss (a picture called "ductopenia") in HL has been described in other 39 other cases in the literature (Table [1](#Tab1){ref-type="table"}). This is a severe complication with a high rate of death in a neoplastic disease otherwise curable in more than 80% of patients. In 18 HL patients steroid plus lymphoma treatment (both chemotherapy and radiotherapy) was described to improve hepatic function and eventually led to complete remission of both hepatic and Hodgkin's diseases. All other cases died because of hepatic failure. A clear pathogenetic relationship between HL and VBDS cannot be identified. Nevertheless, the concomitance of the two diseases and the case reported by Allory \[[@CR3]\] makes the hypothesis of VBDS likely to be a paraneoplastic manifestation of HL. Furthermore, Bruguera \[[@CR4]\] has shown hepatic sinusoidal dilatation (a feature of VBDS) in 90% of patients presenting systemic symptoms (so called B symptoms) without any evidence of direct liver involvement by the lymphoma. This datum suggests the role of HL as the trigger event of cytokine-mediated hepatic damage \[[@CR5]\]. There is evidence that biliary epithelial cells \[[@CR6]\] express major histocompatibility complex (MHC) antigens (both class I and II) as well as adhesion molecules like intercellular adhesion molecule 1 (ICAM-1) in response to cytokines produced by HL. In this context, both types of molecules may contribute to adhesion and cytotoxicity due to T lymphocytes. As of today, there is no recognized treatment for VBDS. We, as well as other authors, used UDCA because of its demonstrated activity in primary biliary cirrhosis. Indeed, beneficial effects of treatment with UDCA have been reported in other immune-mediated disease involving the biliary tree as primary sclerosing cholangitis \[[@CR7]\] or hepatic involvement by graft versus host disease \[[@CR8]\]. UDCA acts at three levels: increasing the expression of transporter proteins into the canalicular membrane, inhibiting apoptosis induced by toxic bile acids, and altering the composition of the micelles of bile acids \[[@CR7]\].Table 1**Summary of all cases reported in the literature regarding vanishing bile duct syndrome in lymphomas**AuthorNumber of patientsHodgkin lymphoma treatment\*DosageUrsodeoxycholic acidOutcomeBouroncle B. \[[@CR9]\]2YesFullUnknownHepatic failureYesReducedHepatic failureJuniper K. \[[@CR10]\]1YesReducedUnknownHepatic failureGroth C. \[[@CR11]\]1YesFullUnknownHepatic failurePerera D.R. \[[@CR12]\]3YesFullUnknownHepatic failureYesFullUnknownCureYesFullUnknownCurePiken E.P. \[[@CR13]\]1YesFullUnknownUnknownTrewby P.N. \[[@CR14]\]4YesFullUnknownCureYesFullUnknownCureYesFullUnknownUnknownNoNoUnknownUnknownLieberman D.A. \[[@CR15]\]1NoNoNoRespiratory arrestBirrer M.J. \[[@CR16]\]1YesFullUnknownSepsisHubscher S.G. \[[@CR1]\]3YesReducedNoHepatic failureJansen P.L.M. \[[@CR17]\]1YesFullLateHepatic failureWarner A.S. \[[@CR18]\]1YesFullNoCureGottrand F. \[[@CR19]\]1NoNoNoHepatic failureCrosbie O.M. \[[@CR20]\]1YesFullYesCureDe Medeiros B.C. \[[@CR21]\]2YesFullNoHepatic failureFullYalcin S. \[[@CR22]\]2NoNoNoHepatic failureYesFullNoCureDourakis S.P. \[[@CR23]\]1YesReducedNoHepatic failureYusuf M.A. \[[@CR24]\]1NoNoLateHepatic failureRossini M.S. \[[@CR25]\]1YesFullNoHepatic failureAllory Y. \[[@CR3]\]1YesFullYesCureOzkan A. \[[@CR26]\]1NoNoLateHepatic failureRipoll C. \[[@CR27]\]2YesFullNoHepatic failureYesFullYesCureKomurcu S. \[[@CR28]\]1YesFullNoHepatic failureLiangpunsakul S. \[[@CR29]\]1YesFullNoCureGuliter S. \[[@CR30]\]1YesFullLateHepatic failureCórdoba Iturriagagoitia A. \[[@CR31]\]1YesFullNoCureHan W.S. \[[@CR32]\]1NoNoNoRecurrent Hodgkin's LymphomaSchmitt A. \[[@CR33]\]1NoNoNoHepatic failureBarta S.K. \[[@CR34]\]1YesFullNoCureDeBenedet A.T. \[[@CR35]\]1YesReducedNoHepatic failureLeeuwenburgh I. \[[@CR36]\]1YesReducedNoCurePass A.K. \[[@CR37]\]2YesReducedYesCureYesReducedNoHepatic failureBallonoff A. \[[@CR38]\]1YesFullNoCureUmit H. \[[@CR39]\]1UnknownUnknownUnknownUnknownGill R.M. \[[@CR40]\]1YesReducedNoHepatic failureForamiti S. \[[@CR41]\]1YesFullYesHepatic failureGagnon MF \[[@CR42]\]1YesFullNoCureWong KM \[[@CR43]\]1YesFullNoCureAleem A1 \[[@CR44]\]1YesFullNoHepatic failureNader K \[[@CR45]\]1YesFullNoHepatic failureOur patient1YesFullYesCure\*either chemotherapy or radiotherapy.

In the present report we stress two aspects. First, the therapeutic choice to use high-dose of UDCA \[[@CR46]\] and prednisone which rapidly determined an improvement of our patients. Secondly, although still icteric, we delivered a full dose chemotherapy achieving a sustained complete remission that, in a paraneoplastic disease, is the most important result. An appropriate aggressive treatment (either chemotherapy or radiotherapy) was reported in all patients who were, in the end, cured (Table [1](#Tab1){ref-type="table"}). Notwithstanding, several good reasons stand for a dose reduction in both doxorubicin and vinblastine in a jaundiced patient, we emphasize the "full dose" chemotherapy choice. ABVD chemotherapy is conceived as a 2-weekly treatment and, therefore, 25 mg/m^2^ doxorubicin was felt appropriate regardless of jaundice. Indeed, it is half the dose used in other combinations (*e.g.* CHOP regimen - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone or CODOX-M/IVAC -- Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Ifosfamide, Etoposide, Cytarabine \[[@CR47], [@CR48]\]). Moreover, it is well known that the ABVD dose intensity affects the HL outcome \[[@CR49], [@CR50]\]. Lastly, only 1 out of 8 (12%) patients receiving an upfront reduced chemotherapy overcame the vanishing bile duct, compared to 51% (17/33) of patients treated with upfront full dose chemotherapy (see Table [1](#Tab1){ref-type="table"}). In these patients the efficacious treatment of the lymphoma preceded the hepatic improvement and, ultimately, the cure.

This case report demonstrates that in the presence of a histological diagnosis of HL associated with signs of cholestasis and liver function impairment without gross liver involvement or biliary tract dilatation, the prompt treatment of the underlying disease in association with high doses of UDCA is crucial. Indeed, data available in the literature strengthen the theory that the therapy able to restore liver function is full dose chemotherapy only. In this setting, waiting for the histological confirmation of VBDS may be harmful because a delayed start might be detrimental to patient outcome. Indeed, liver impairment could evolve to liver insufficiency and eventually to death as is clearly outlined in Table [1](#Tab1){ref-type="table"}.

In conclusion, VBDS must be considered a rare but possible complication of HL. Its prompt recognition and appropriate treatment can dramatically affect patients' outcome.

Consent {#Sec4}
=======

Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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